Literature DB >> 7817261

Clinical course and prognostic factors of human papillomavirus infections in men.

M I Hippeläinen1, M Hippeläinen, S Saarikoski, K Syrjänen.   

Abstract

BACKGROUND AND OBJECTIVES: Biological behavior of male genital human papillomavirus (HPV) infection is incompletely understood, and the clinical value of treatment is obscure. GOAL OF THIS STUDY: To evaluate the clinical course and possible prognostic factors of genital HPV infections in men. STUDY
DESIGN: A total of 318 consecutive high-risk men for HPV infection (94.3% partners of HPV-infected women) were examined using peniscopy, histology, cytology, and in situ hybridization (ISH). Only the men with exophytic warts or clinical symptoms were treated, if they insisted on it (n = 55). The others with (n = 150) or without (n = 113) HPV suggestive lesions were followed-up only at 6-month intervals. Survival analysis was used to calculate the cure rates in different subgroups of the males, categorized according to the potential prognostic factors (i.e., age, treatment, lesion morphology, HPV type, female findings, and sexual habits).
RESULTS: The calculated median cure time of the HPV-positive men was 15.2 months (95% confidence interval 12.2-21.3 months) and it did not differ significantly in the male groups treated or only followed-up (P = 0.56). In univariate survival analysis, only the ISH-positivity (P = 0.002) and the anamnestic use of condom (P = 0.05) were significant prognostic factors. The condom use also had a protective effect (P = 0.04) against the appearance of new HPV-suggestive lesions in initially healthy males. Although the treatment did not significantly affect the overall cure rate, the number of lesions decreased, however, after therapy (i.e., fewer widespread infections), and the appearance of new HPV lesions seemed to be less frequent in the treated than in nontreated males.
CONCLUSIONS: The low success rate of therapy and the obviously benign clinical course of all subclinical HPV lesions of the male genitalia justify the follow-up of all lesions with HPV-suspicious morphology only. On the other hand, treatment seems to exert a favorable effect on clinical HPV infections, new exophytic warts and penile intraepithelial lesions (PIN) lesions being rare in adequately treated males.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7817261     DOI: 10.1097/00007435-199409000-00005

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  6 in total

1.  Dynamics of genital human papillomavirus (HPV) infections among males eventually being uncovered.

Authors:  Kari Syrjänen
Journal:  Asian J Androl       Date:  2011-04-18       Impact factor: 3.285

2.  Anogenital warts and condom use--a survey of information giving.

Authors:  H L McClean; R J Hillman
Journal:  Genitourin Med       Date:  1997-06

Review 3.  Human papillomavirus molecular biology.

Authors:  Mallory E Harden; Karl Munger
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-05       Impact factor: 5.657

4.  Intralesional Purified Protein Derivative of Tuberculin Versus Intralesional Mycobacterium W Vaccine in Treatment of Recalcitrant Extragenital Warts: A Randomized, Single-Blinded, Comparative Study.

Authors:  Alpana Mohta; Suresh Kumar Jain; Rajesh Dutt Mehta; Aakanksha Arora
Journal:  Indian J Dermatol       Date:  2022 Jan-Feb       Impact factor: 1.757

5.  Prevalence and determinants of human papillomavirus genital infection in men.

Authors:  S Franceschi; X Castellsagué; L Dal Maso; J S Smith; M Plummer; C Ngelangel; S Chichareon; J Eluf-Neto; K V Shah; P J F Snijders; C J L M Meijer; F X Bosch; N Muñoz
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

6.  HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions.

Authors:  M C G Bleeker; J Berkhof; C J A Hogewoning; F J Voorhorst; A J C van den Brule; T M Starink; P J F Snijders; C J L M Meijer
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.